Literature DB >> 2970401

Femoro-popliteal artery thrombolysis with intra-arterial infusion of recombinant tissue-type plasminogen activator--report of a pilot trial.

M Verstraete1, H Hess, F Mahler, A Mietaschk, F J Roth, E Schneider, A L Baert, R Verhaeghe.   

Abstract

Recombinant tissue-type plasminogen activator (rt-PA) was infused at a rate of 10 mg/h into 50 thrombosed femoral and popliteal arteries. Patency was restored in 43 but a secondary angioplasty led to 2 reocclusions and in 3 patients early rethrombosis occurred. A favourable clinical result was thus obtained in 38 patients (76%). Thirteen bleeding complications occurred in 10 patients, mainly haematomas at puncture sites. One patient required blood transfusion for gastro-intestinal bleeding from a previously unknown ulcer. The angiographic recanalisation rate in 16 patients who received a slower infusion of rt-PA (5 or 3 mg/h) was 94% and the clinical success rate in this series was 81%. However, the incidence of bleeding complications was not decreased by the slower infusion rate. The data obtained confirm the feasibility of rt-PA thrombolysis in peripheral arterial thrombosis and warrant a comparative study with streptokinase.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2970401     DOI: 10.1016/s0950-821x(88)80068-9

Source DB:  PubMed          Journal:  Eur J Vasc Surg        ISSN: 0950-821X


  6 in total

1.  Segmentally enclosed thrombolysis in percutaneous transluminal angioplasty for femoropopliteal occlusions: a report from a pilot study.

Authors:  B Jørgensen; K H Tønnesen; J D Nielsen; P Holstein; J Bülow; M Jørgensen; E Andersen
Journal:  Cardiovasc Intervent Radiol       Date:  1991 Sep-Oct       Impact factor: 2.740

Review 2.  Intra-arterial thrombolysis should be the initial treatment of the acutely ischaemic lower limb.

Authors:  D R Allen; J Smallwood; C D Johnson
Journal:  Ann R Coll Surg Engl       Date:  1992-03       Impact factor: 1.891

Review 3.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

4.  Efficacy and tolerance of recombinant tissue-type plasminogen activator in patients with thrombotic or embolic occlusions of leg-arteries.

Authors:  F A Spengel; G Küffer; H Stiegler
Journal:  Clin Investig       Date:  1993-04

Review 5.  Comparative tolerability profiles of thrombolytic agents. A review.

Authors:  K S Woo; H D White
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

Review 6.  Use of thrombolytic drugs in non-coronary disorders.

Authors:  M Verstraete
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.